Cancer Research Consortium of West Michigan
P: 616.391.1230 | 800.336.6299 | www.crcwm.org

Fast Facts

Molecular Analysis for Combination Therapy Choice(ComboMATCH)

Eligibility Criteria Screening

1. Patient must have measurable disease.
2. Patient must have an ECOG performance status between 0-2.

   OR

   Patient must have Lansky performance status of ≥ 50% or Karnofsky performance status of ≥ 50%.
3. Patient must be deemed potentially eligible for a ComboMATCHTreatment Trial as assessed by the enrolling provider.
4. All patients must have sequencing results available from an NCI credentialed Designated Laboratory (DL).
5. Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of thefollowing criteria:
   - Patients must have progressed on at least one line of standardsystemic therapy.

     OR
   - Patients whose disease has no standard treatment that has beenshown to prolong overall survival.
6. Patient must meet one of the following requirements:

   i. Patients 18 years and older who have tumor amenableto minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsyto obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial.

   OR

   ii. Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumortissue must meet the following criteria:
   - Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial
   - Patient must not have had a RECIST response (CRor PR) to any intervening therapy after collection of the tissue
   - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available (see Section5.3).

   OR

   iii. Patients under 18 years old must confirm willingness to submit an archival tumor tissue specimen for submission, if available, for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
   - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available (see Section5.3).

NOTE: **See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions.**
Performance of the mandatory research biopsy or submissionof pre-trial FFPE and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only.

NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial.

Schema